Table 3 Multivariable analysis of the differences between reclassified or not reclassified patients

cIMT, μm

650 ± 140

740 ± 140

0.000

Age, years

54 ± 14

62 ± 9

0.000

Female, n (%)

531 (78)

437 (76)

0.40

BMI, kg/m²

27 ± 6

28 ± 5

0.39

Abdominal circumference, cm

94 ± 15

94 ± 14

0.92

  Current smoker

169 (25)

153 (26)

0.47

  Obesity

193 (28)

155 (27)

0.58

  Dyslipidemia

275 (40)

332 (57)

0.000

  Hypertension

192 (28)

271 (47)

0.000

  Systolic

130 ± 18

132 ± 16

0.024

  Diastolic

78 ± 10

79 ± 9

0.58

  Total cholesterol, mmol/l

5.26 ± 0.96

5.28 ± 0.96

0.66

  Triglycerides, mmol/l

1.24 ± 0.71

1.28 ± 0.68

0.35

  HDL cholesterol, mmol/l

1.58 ± 0.44

1.58 ± 0.44

0.90

  LDL cholesterol, mmol/l

3.10 ± 0.80

3.10 ± 0.83

0.94

  Atherogenic index

3.56 ± 1.11

3.53 ± 0.97

0.63

 Statins, n (%)

113 (17)

188 (33)

0.000

 Aspirin, n (%)

16 (2)

27 (5)

0.018

 Antihypertensive treatment, n (%)

140 (20)

190 (33)

0.000

 Disease duration, years

5 (2–12)

5 (2–12)

0.62

 CRP at time of study, mg/l

2.5 (0.9–6.4)

3.0 (1.0–7.0)

0.71

 ESR at time of study, mm/ 1° hour

11 (5 − 21)

13 (6–25)

0.007

1.00 (0.99–1.01), 0.79

 Rheumatoid factor, n (%)

380 (56)

360 (62)

0.019

1.58 (1.19–2.11), 0.002

 ACPA, n (%)

352 (51)

320 (55)

0.097

1.46 (1.09–1.94), 0.011

 DAS28-ESR

2.96 ± 1.50

3.27 ± 1.46

0.000

1.09 (1.02–1.19), 0.028

 DAS28-PCR

2.91 ± 1.28

3.10 ± 1.28

0.010

1.04 (0.93–1.16), 0.095

 SDAI

3.20 ± 2.05

3.10 ± 2.02

0.73

 CDAI

8 (3–16)

9 (4–17)

0.078

1.00 (0.99–1.02), 0.52

 HAQ

0.690 (0250–1.250)

0.750 (0250–1.250)

0.36

 RAPID

3.20 ± 2.05

3.10 ± 2.02

0.61

  Prednisone

330 (48)

291 (50)

0.46

  Prednisone doses, mg/day

5 (2.5–6)

5 (5–7.5)

0.42

  NSAIDs

282 (41)

205 (35)

0.036

0.93 (0.70–1.24), 0.62

  DMARDs

525 (77)

444 (77)

0.98

  Methotrexate

395 (58)

324 (56)

0.55

  Leflunomide

70 (10)

68 (12)

0.39

  Hydroxychloroquine

147 (21)

132 (23)

0.57

  Sulphasalazine

19 (3)

24 (4)

0.18

1.69 (0.84–3.41), 0.15

  Anti-TNF therapy

91 (13)

72 (12)

0.66

   Adalimumab

26 (4)

28 (5)

0.36

   Infliximab

12 (2)

6 (1)

0.29

   Etanercept

40 (6)

26 (4)

0.28

   Golimumab

1 (0)

3 (1)

0.34

  Tocilizumab

37 (5)

27 (5)

0.56

  Rituximab

9 (1)

11 (2)

0.40

  Abatacept

8 (1)

13 (2)

0.14

2.13 (0.77–5.97), 0.15

  Baricitinib

5 (1)

6 (1)

0.56

  Tofacitinib

9 (1)

5 (1)

0.45

 History of extraarticular manif., n (%)

112 (16)

119 (21)

0.058

1.07 (0.75–1.52), 0.72

 Erosions, n (%)

230 (34)

216 (37)

0.048

1.26 (0.93–1.72), 0.13

 CRP at time of disease diagnosis, mg/l

7 (2–19)

8 (3–22)

0.28

 CRP > 3 at time of diagnosis, n (%)

354 (52)

324 (56)

0.068

1.13 (0.78–1.64), 0.52

 ESR at the time of diagnosis, mm/1st hour

20 (11–37)

23 (12–40)

0.28